



DAILY COVID-19 UPDATE

November 10, 2020

WHAT HAPPENED TODAY

In a Dear Colleague [letter](#), House Majority Leader Steny Hoyer (D-MD) indicated the "top priority" for the chamber continues to be enacting COVID-19 relief legislation. Senate Majority Leader Mitch McConnell (R-KY) agreed, stating Congress should pass a limited stimulus bill by the end of 2020. However, Leader McConnell pointed to a lower unemployment rate and higher GDP growth as factors that a multi-trillion dollar package is unnecessary.

Meanwhile President-elect Joe Biden [warned](#) of a "dark winter ahead," stressing that masks are the "most potent weapon against the virus." He added that the goal of mask wearing "is not to make your life less comfortable or take something away from you. It's to give something back to all of us -- a normal life."

Leader McConnell [echoed](#) Biden's words, stating, "We cannot give up on common-sense measures like wearing masks just because we've grown tired of them."

LATEST STATISTICS

There are a total of **51,248,841** confirmed cases worldwide, 1,268,452 deaths and 33,459,967 people have recovered.

There are **10,180,798** confirmed cases of the coronavirus in the U.S., 239,002 deaths and 3,928,845 people have recovered.

Yesterday, the U.S. surpassed 10 million confirmed COVID-19 cases.

LATEST PMJ RESOURCES

[Lame Duck Preview Memo](#)

[Drug Shortage and Medical Supply Chain Tracker](#)

Since our last update, the Food and Drug Administration published additional guidance related to the pandemic. Please see below for more details.

We have updated our Drug Shortage and Medical Supply Chain Tracker. It is listed under Latest PMJ Resources.

[Coronavirus State Reopening Tracker](#)

[President Trump EO Tracker](#)

[COVID-19 Legislative Outlook](#)

[State Responses to EO on Unemployment Insurance](#)

[Healthcare Chart on COVID Legislation](#)

[Liability Reform State of Play](#)

[CARES Act State Funding](#)

[State and Local Funding Bills](#)

[COVID Legislative Tracker](#)

[Global COVID-19 Export Controls](#)

[Memo - Federal Reserve COVID-19 Announcements](#)

[Federal Reserve Lending Facilities Deck](#)

ECONOMIC UPDATE

Congress SENATE

- Senate Banking Committee Chairman Mike Crapo's (R-ID) [statement](#) at the Financial Regulator Oversight hearing.

Administration

FEDERAL RESERVE ("FED")

- The Fed [announced the approval](#) of fee schedules, effective January 2021, for payment services the federal Reserve Banks provide to depository institutions.

OFFICE OF THE COMPTROLLER OF THE CURRENCY (OCC)

- The OCC reported the key issues facing the federal banking system and the effects of the COVID-19 pandemic on the federal banking industry in its [Semiannual Risk Perspective for Fall 2020](#).

Articles of Interest

- 11/10 The Wall Street Journal published an article titled, [“U.S. Job Openings Are Rising Closer to Pre-Coronavirus Levels.”](#)
- 11/9 The Wall Street Journal published an article titled, [“Fed Says Coronavirus Remains a Top U.S. Financial Risk.”](#)

PUBLIC HEALTH UPDATE

Congressional

HOUSE

- House Majority Leader Steny Hoyer (D-MD) penned a [Dear Colleague letter](#) to provide an update on the floor schedule for November and December.
- Speaker Nancy Pelosi (D-CA) released a [statement](#) on the announcement by Pfizer and BioNTech about their COVID-19 vaccine candidate.

SENATE

- Senate Majority Leader Mitch McConnell (R-KY) delivered [remarks](#) on the Senate floor regarding COVID-19 vaccine developments and the falling unemployment rate.

Administration

DEPARTMENT OF HEALTH AND HUMAN SERVICES

- HHS [announced](#) plans to allocate initial doses of Eli Lilly and Company's investigational monoclonal antibody therapeutic, bamlanivimab, which received emergency use authorization from the FDA on November 9 for the treatment of non-hospitalized patients with mild or moderate confirmed cases of COVID-19.

FOOD AND DRUG ADMINISTRATION

- The FDA issued an [emergency use authorization \(EUA\)](#) for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients.
- The FDA [issued final guidance](#) with the agency's recommendations on designing and executing clinical trials of drugs and biologics that include people with different demographic characteristics (e.g., sex, race, ethnicity, age) and non-demographic characteristics (e.g., patients with organ dysfunction, comorbid conditions, and disabilities.) This is particularly critical during the COVID-19 public health emergency as certain segments of the population are being affected by the virus in different ways.

Articles of Interest

- 11/9 The New York Times published an article titled, [“Eli Lilly's Antibody Treatment Gets Emergency F.D.A. Approval.”](#)
- 11/9 NPR published an article titled, [“Operation Warp Speed's Logistics Chief Weighs In On Vaccine Progress.”](#)
- 11/9 The Wall Street Journal published an article titled, [“Joe Biden Kicks Off Transition Focused on Coronavirus.”](#)

- 11/10 The New York Times published an op-ed from professors of law and pediatrics titled, **“Don’t Get Too Excited About the Coronavirus Vaccine.”**
- 11/10 Stat published an article titled, **“How might a mask mandate play out? Look to the battle over seat belt laws.”**